Clinically meaningful response to avatrombopag for treatment of pediatric immune thrombocytopenia: : Post-Hoc Analyses from the AVA-PEDS-301 Phase 3 Study

• JSH •
• 10 October, 2025 •
• •

One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults

Hiroki Yamaguchi, Masaki Iino, Yoshiaki Tomiyama , Harumi Kamiya, Jessica Zhang, Nina Skuban

• ISTH •
• 24 June, 2025 •
• •

Analysis of Baseline Influences on Platelet Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Pati

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Michael Vredenburg , Scott Kolodny

Available materials

• ISTH •
• 24 June, 2025 •
• •

Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure

Srikanth Nagalla, Moshe Y Levy, Shruti Chaturvedi, Scott Kolodny, Abiola Oladapo, Chelsea Bernheisel, Elyse Swallow, Debbie Goldschmidt, Alexandra Greatsinger, Loren Ormenaj, Sinia Sareen, Michael Vredenburg

Available materials

• ISTH •
• 22 June, 2025 •
• •

Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian Jamieson, Michael Vredenburg , Scott Kolodny

Available materials